At Ther-Rx, we understand that even the most effective medications won’t work if patients have difficulty taking them. Issues like convenience and tolerability can often determine whether or not patients will consistently take the medications prescribed by their physicians.

We use advanced drug-delivery technologies from our parent company – KV Pharmaceutical Company – to create medications that provide patient advantages such as reduced dosing regimen, improved compliance, medications that are easier to take, act faster or last longer

By applying these highly advanced drug delivery technologies in patient-friendly ways, we are striving to delivery "best-in-class" compliance and patient satisfaction

Since establishment in 1999, Ther-Rx Corporation has reported a consistent revenue growth record, compounding its net revenues on an annual basis over the last four years 44.2%. Fiscal 2007 revenues were $188.7 up 16% over fiscal 2006 revenues of $145.4. Ther-Rx enjoys average gross margins of 89%.

Today at Ther-Rx we are:

Marketers of leading one-dose vaginal anti-infective products

  Launching Evamist™, the first and only estradiol transdermal spray indicated for the treatment of moderate-to-severe vasomotor symptoms due to menopause. Please see full prescribing information including the black box warning

Focusing on these categories allows Ther-Rx to maximize its national sales force which promotes our products directly to a defined group of targeted specialty physicians, primarily obstetrics and gynecology. Since 1999, this focused strategy has successfully turned Ther-Rx into a premiere marketer of branded women’s health products and an increasingly significant part of the overall business of parent company KV Pharmaceutical Company.